BTL introduces EMFACE Eye, a new non-invasive device targeting under-eye aging by restoring muscle tone and soft tissue support.
BTL Industries has announced the launch of EMFACE Eye, a new device intended to treat under-eye aging through non-invasive means. EMFACE Eye marks an expansion of the company’s EMFACE platform and is designed to restore muscle tone and soft tissue support in the periorbital region without the need for surgery or injectables.
The launch follows significant growth for the company, with EMFACE surpassing 1 million treatments globally and a 70% year-over-year sales increase in North America in Q1 2025.
A Focus on the Under-Eye Area
The under-eye region has traditionally posed challenges for non-surgical aesthetic procedures due to its delicate anatomy and tendency toward issues like puffiness, dark circles, and volume loss. EMFACE Eye targets the lower orbicularis oculi muscle to lift and support soft tissue, offering an alternative or adjunct to injectables, according to the company.
BTL reports that in a typical 20-minute session, patients experienced a 1.4mL reduction in under-eye volume, a 28% reduction in crow’s feet, and a 64% decrease in dark circles—all without downtime.
Clinical Perspective and Platform Expansion
Melanie Palm, MD, MBA, a cosmetic dermatologist in California, noted that EMFACE Eye provides meaningful structural support to the infraorbital area, reducing fat pseudo-herniation and improving overall appearance. “As a cosmetic dermatologist with a sizeable injectable practice, this is exactly what I’ve been waiting for. The results include noticeable brightening of the under-eye and buttressing of the infraorbital fat pad, significantly reducing fat pseudo-herniation. Emface restores structure and function to the facial anatomy in the most natural way, so we can count on superior results that drive high patient satisfaction,” said Palm.
With the Eye applicators, the EMFACE platform now supports full-face aesthetic treatment, including forehead lifting, jawline sculpting, and periorbital enhancement. According to BTL, this enables a layered, non-invasive approach that integrates well with existing injectable protocols.
BTL Eyes Continued Growth in Aesthetic Market
EMFACE Eye’s release reinforces BTL’s position in the growing non-invasive facial aesthetics segment. The company says the platform is designed to meet increasing patient demand for natural-looking results without surgical intervention or downtime.
Photo: ID 175406582 © Karel Noppe | Dreamstime.com
